WENTWORTH KORY JAMES 4
4 · Entrada Therapeutics, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Entrada Therapeutics (TRDA) CFO Kory Wentworth Sells Shares
What Happened Kory James Wentworth, CFO of Entrada Therapeutics, reported sales of company stock in two transactions. On 2026-03-09 he sold 5,089 shares at a reported weighted-average price of $13.00 for $66,163, and on 2026-03-10 he sold 11,388 shares at a reported weighted-average price of $13.02 for $148,216 — total 16,477 shares and roughly $214,379 in proceeds. These were disposals (sales), not purchases.
Key Details
- Transaction dates: March 9, 2026 (5,089 shares @ $13.00, $66,163) and March 10, 2026 (11,388 shares @ $13.02, $148,216).
- Aggregate sold: 16,477 shares for ~$214,379. Method listed as open market or private sale (Form 4 code S).
- Footnotes: Trades were executed under a Rule 10b5-1 trading plan adopted March 6, 2025 (F1). Price reporting uses weighted averages; March 9 sales ranged $12.95–$13.14 (F2) and March 10 sales ranged $12.95–$13.20 (F3). The filer can provide a per-price breakdown on request.
- Shares owned after the transactions: Not disclosed in the excerpt of this filing.
- Filing: Form 4 filed with the SEC on March 11, 2026 (no late-filing flag shown in the provided data).
Context Sales under a 10b5-1 plan are pre‑planned and are commonly used by insiders to regularly liquidate holdings; they do not necessarily signal a change in company outlook. For retail investors, purchases are generally more informative about insider conviction; this filing documents routine disposals by the CFO totaling about $214k.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-09$13.00/sh−5,089$66,163→ 132,898 total - Sale
Common Stock
[F1][F3]2026-03-10$13.02/sh−11,388$148,216→ 121,510 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.